SCHEMBL5463862

SCHEMBL5463862

O=C(OCc1ccccc1)c1cc(/C=C2/SC(=O)N(CCc3ccc(Cl)cc3)C2=O)ccc1O

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ ALDH1A1 P00352 1/20 0.51
▸ LMNA P02545 1/20 0.51
▸ POLB P06746 1/20 0.51
▸ MAPT P10636 1/20 0.51
▸ MAPK1 P28482 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ S1PR1 P21453 1/20 0.50
▸ S1PR3 Q99500 1/20 0.50
▸ PTPN1 P18031 8/20 0.47
▸ ACP1 P24666 8/20 0.47
▸ CA9 Q16790 1/20 0.47
▸ PTPN2 P17706 5/20 0.47
▸ ENPP2 Q13822 4/20 0.47
▸ PTPRF P10586 1/20 0.47
▸ PTPRB P23467 1/20 0.47
▸ AKR1B1 P15121 1/20 0.46
▸ PPARG P37231 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5463865 1.00 KDM4E (0.51) KDM4EMEN1ALDH1A1LMNAPOLB
SCHEMBL5465180 0.86 CA9 (0.55) KDM4EMEN1ALDH1A1LMNAPOLB
SCHEMBL5469982 0.86 CA9 (0.55) KDM4EMEN1ALDH1A1LMNAPOLB
SCHEMBL5464400 0.82 ENPP2 (0.70) PTPN1ACP1PTPN2ENPP2PTPRF
SCHEMBL5464405 0.82 ENPP2 (0.70) PTPN1ACP1PTPN2ENPP2PTPRF
SCHEMBL5455135 0.81 MAPK1 (0.59) MEN1ALDH1A1POLBMAPTMAPK1
SCHEMBL5455133 0.81 MAPK1 (0.59) MEN1ALDH1A1POLBMAPTMAPK1
SCHEMBL5460594 0.81 PTPN1 (0.54) MEN1POLBKMT2APTPN1ACP1
SCHEMBL5460593 0.81 PTPN1 (0.54) MEN1POLBKMT2APTPN1ACP1
SCHEMBL5465629 0.79 PTPN1 (0.56) KDM4EMEN1POLBMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2007-11-29 — — US disclosed
EP-1666469-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Institute of Medicinal Molecular Design, Inc. (JP) 2006-06-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 KDM4E 3789/4885MEN1 2892/4885ALDH1A1 1861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback